212 related articles for article (PubMed ID: 32341207)
1. The effect of veno-arterial extracorporeal oxygenation and nasogastric tube administration on the pharmacokinetic profile of abacavir, lamivudine and dolutegravir: a case report.
Blackman AL; Heil EL; Devanathan AS; Pandit NS
Antivir Ther; 2020; 25(2):115-119. PubMed ID: 32341207
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics, Safety, and Tolerability of a Single Oral Dose of Abacavir/Dolutegravir/Lamivudine Combination Tablets in Healthy Japanese Study Participants.
Singh RP; Adkison K; Wolstenholme A; Hopking J; Wynne B
Clin Pharmacol Drug Dev; 2021 Sep; 10(9):985-993. PubMed ID: 34265164
[TBL] [Abstract][Full Text] [Related]
3. Case Report of Increased Exposure to Antiretrovirals following Sleeve Gastrectomy.
Israel S; Elinav H; Elazary R; Porat D; Gibori R; Dahan A; Azran C; Horwitz E
Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 32015045
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness and tolerability of dolutegravir and abacavir/lamivudine administered as two separate pills compared to their equivalent single-tablet regimen in a multicentre cohort in Spain.
Suárez-García I; Alejos B; Ruiz-Algueró M; García Yubero C; Moreno C; Bernal E; Pérez-Is L; Zubero Z; de Zárraga Fernández MA; Samperiz Abad G; Jarrín I;
J Int AIDS Soc; 2021 Jul; 24(7):e25758. PubMed ID: 34291580
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic profiles of boosted darunavir, dolutegravir and lamivudine in aging people living with HIV.
Courlet P; Stader F; Guidi M; Alves Saldanha S; Stoeckle M; Cavassini M; Battegay M; Buclin T; Decosterd LA; Marzolini C;
AIDS; 2020 Jan; 34(1):103-108. PubMed ID: 31490233
[TBL] [Abstract][Full Text] [Related]
6. Bioequivalence and Food Effect Assessment of 2 Fixed-Dose Combination Formulations of Dolutegravir and Lamivudine.
Dumitrescu TP; Peddiraju K; Fu C; Bakshi K; Yu S; Zhang Z; Tenorio AR; Spancake C; Joshi S; Wolstenholme A; Adkison K
Clin Pharmacol Drug Dev; 2020 Feb; 9(2):189-202. PubMed ID: 31724343
[TBL] [Abstract][Full Text] [Related]
7. Doing More With Less: Review of Dolutegravir-Lamivudine, a Novel Single-Tablet Regimen for Antiretroviral-Naïve Adults With HIV-1 Infection.
Santevecchi BA; Miller S; Childs-Kean LM
Ann Pharmacother; 2020 Dec; 54(12):1252-1259. PubMed ID: 32517480
[TBL] [Abstract][Full Text] [Related]
8. Abacavir/lamivudine/dolutegravir single tablet regimen in patients with human immunodeficiency virus and end-stage renal disease on hemodialysis.
Michienzi SM; Schriever CA; Badowski ME
Int J STD AIDS; 2019 Feb; 30(2):181-187. PubMed ID: 30381029
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness, Safety, and Costs of Dolutegravir/Abacavir/Lamivudine Single-Tablet Regimen in a Real-Life Cohort of HIV-1 Adult Infected Patients.
Rodriguez-Gonzalez CG; Chamorro-de-Vega E; Ortega-Navarro C; Alonso R; Herranz-Alonso A; Sanjurjo-Saez M
Ann Pharmacother; 2020 Jul; 54(7):633-643. PubMed ID: 31910643
[No Abstract] [Full Text] [Related]
10. Enhanced Solubility and Bioavailability of Dolutegravir by Solid Dispersion Method: In Vitro and In Vivo Evaluation-a Potential Approach for HIV Therapy.
Chaudhary S; Nair AB; Shah J; Gorain B; Jacob S; Shah H; Patel V
AAPS PharmSciTech; 2021 Apr; 22(3):127. PubMed ID: 33835317
[TBL] [Abstract][Full Text] [Related]
11. Drug-Drug Interaction between the Direct-Acting Antiviral Regimen of Ombitasvir-Paritaprevir-Ritonavir plus Dasabuvir and the HIV Antiretroviral Agent Dolutegravir or Abacavir plus Lamivudine.
Khatri A; Trinh R; Zhao W; Podsadecki T; Menon R
Antimicrob Agents Chemother; 2016 Oct; 60(10):6244-51. PubMed ID: 27503645
[TBL] [Abstract][Full Text] [Related]
12. Bioequivalence of a dolutegravir, abacavir, and lamivudine fixed-dose combination tablet and the effect of food.
Weller S; Chen S; Borland J; Savina P; Wynne B; Piscitelli SC
J Acquir Immune Defic Syndr; 2014 Aug; 66(4):393-8. PubMed ID: 24798770
[TBL] [Abstract][Full Text] [Related]
13. Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.
Molina JM; Ward D; Brar I; Mills A; Stellbrink HJ; López-Cortés L; Ruane P; Podzamczer D; Brinson C; Custodio J; Liu H; Andreatta K; Martin H; Cheng A; Quirk E
Lancet HIV; 2018 Jul; 5(7):e357-e365. PubMed ID: 29925489
[TBL] [Abstract][Full Text] [Related]
14. D3/Penta 21 clinical trial design: A randomised non-inferiority trial with nested drug licensing substudy to assess dolutegravir and lamivudine fixed dose formulations for the maintenance of virological suppression in children with HIV-1 infection, aged 2 to 15 years.
Turkova A; Chan MK; Kityo C; Kekitiinwa AR; Musoke P; Violari A; Variava E; Archary M; Cressey TR; Chalermpantmetagul S; Sawasdichai K; Ounchanum P; Kanjanavanit S; Srirojana S; Srirompotong U; Welch S; Bamford A; Epalza C; Fortuny C; Colbers A; Nastouli E; Walker S; Carr D; Conway M; Spyer MJ; Parkar N; White I; Nardone A; Thomason MJ; Ferrand RA; Giaquinto C; Ford D;
Contemp Clin Trials; 2024 Jul; 142():107540. PubMed ID: 38636725
[TBL] [Abstract][Full Text] [Related]
15. Crushing of dolutegravir fixed-dose combination tablets increases dolutegravir exposure.
Roskam-Kwint M; Bollen P; Colbers A; Duisenberg-van Essenberg M; Harbers V; Burger D
J Antimicrob Chemother; 2018 Sep; 73(9):2430-2434. PubMed ID: 29796595
[TBL] [Abstract][Full Text] [Related]
16. Population pharmacokinetic modeling of dolutegravir/lamivudine to support a once-daily fixed-dose combination regimen in virologically suppressed adults living with HIV-1.
Chandasana H; Singh R; Adkison K; Ait-Khaled M; Pene Dumitrescu T
Antimicrob Agents Chemother; 2024 May; 68(5):e0150423. PubMed ID: 38587380
[TBL] [Abstract][Full Text] [Related]
17. Development of Dolutegravir Single-entity and Fixed-dose Combination Formulations for Children.
Singh RP; Adkison KK; Baker M; Parasrampuria R; Wolstenholme A; Davies M; Sewell N; Brothers C; Buchanan AM
Pediatr Infect Dis J; 2022 Mar; 41(3):230-237. PubMed ID: 34817414
[TBL] [Abstract][Full Text] [Related]
18. Lamivudine plus dolutegravir as a switch strategy in children: three case reports.
Labate L; Bartalucci C; Taramasso L; Brucci G; Vena A; Bassetti M; Di Biagio A
New Microbiol; 2024 May; 47(1):111-115. PubMed ID: 38700892
[TBL] [Abstract][Full Text] [Related]
19. Effects of Low- and High-Mineral Content Water on the Relative Bioavailability of a Coformulated Abacavir/Dolutegravir/Lamivudine Dispersible Tablet in Healthy Adults.
Singh RP; Shaik JSB; Skoura N; Joshi S; Shreeves T; Casillas L; Buchanan AM
J Acquir Immune Defic Syndr; 2018 Dec; 79(5):631-638. PubMed ID: 30239425
[TBL] [Abstract][Full Text] [Related]
20. Point-of-Care Detection of Nonadherence to Antiretroviral Treatment for HIV-1 in Resource-Limited Settings Using Drug Level Testing for Efavirenz, Lopinavir, and Dolutegravir: A Validation and Pharmacokinetic Simulation Study.
Hermans LE; Nijhuis M; Tempelman HA; Houts T; Schuurman R; Burger DM; Wensing AMJ; ter Heine R
J Acquir Immune Defic Syndr; 2021 Aug; 87(4):1072-1078. PubMed ID: 34153013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
